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Oran and 10) Hôpital de Boufarik, Blida, AlgeriaAbstractPneumococcal infections are a major cause of morbidity and mortality in developing countries. The introduction of pneumococcal conjugate
vaccines (PCVs) has dramatically reduced the incidence of pneumococcal diseases. PCVs are not currently being used in Algeria. We
conducted a prospective study from 2005 to 2012 in Algeria to determine antimicrobial drug resistance and serotype distribution of
Streptococcus pneumoniae from children with pneumococcal disease. Among 270 isolated strains from children, 97 (36%) were invasive
disease; of these, 48% were not susceptible to penicillin and 53% not susceptible to erythromycin. A high rate of antimicrobial
nonsusceptibility was observed in strains isolated from children with meningitis. The serotype distribution from pneumococci isolated
from children with invasive infections was (by order of prevalence): 14, 1, 19F, 19A, 6B, 5, 3, 6A and 23F. Multidrug resistance was
observed in serotypes 14, 19F, 19A and 6B. The vaccine coverage of serotypes isolated from children aged <5 years was 55.3% for
PCV7, 71.1% for PCV10 and 86.8% for PCV13. Our results highlight the burden of pneumococcal disease in Algeria and the increasing
S. pneumoniae antibiotic resistance. The current pneumococcal vaccines cover a high percentage of the circulating strains. Therefore,
vaccination would reduce the incidence of pneumococcal disease in Algeria.
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E-mail: nramdanidz@yahoo.frIntroductionStreptococcus pneumoniae is a leading respiratory pathogen that
is responsible for infections such as pneumonia, meningitis,
bacteremia and otitis media. In 2003, the World Healthw Microbe and New Infect 2015; 6: 42–48
w Microbes and New Infections © 2015 The Authors. Published by Elsevier Ltd on behalf of
is is an open access article under the CC BY-NC-SA license (http://creativecommons.org/lice
p://dx.doi.org/10.1016/j.nmni.2015.02.008Organization (WHO) estimated that pneumococcal disease is
responsible for 1 million deaths annually, most of which occur
in children <5 years of age in the developing world [1].
Although pneumococcal meningitis is relatively rare, it is
strongly associated with mortality or subsequent neurologic
damage [2].
Pneumococcal resistance to penicillin was ﬁrst described in
1967, and since the 1990s an increasing rate of resistance has
been reported worldwide [3,4]. This resistance makes the
treatment of serious pneumococcal infections difﬁcult, and
many antibiotic treatment failures have been reported [5].European Society of Clinical Microbiology and Infectious Diseases
nses/by-nc-sa/4.0/)
NMNI Ramdani-Bouguessa et al. Antimicrobial resistance in Algeria 43In Algeria, several reports have shown an increase in anti-
biotic resistance from 1996 to 2010, especially among children
[6–9]. Although epidemiologic surveillance data for invasive
pneumococcal infections are available, clinical data are lacking.
Moreover, since the introduction of Haemophilus inﬂuenzae
type b vaccination in 2008 in Algeria, S. pneumoniae has become
the predominant pathogen in bacterial meningitis (unpublished
data).
The S. pneumoniae polysaccharide capsule is a major viru-
lence factor; more than 90 serotypes have been identiﬁed, and
their distribution differs in different regions and between
developing and developed countries [10]. This highlights the
importance of having national data before implementation of a
pneumococcal vaccine. The aim of the study was to investigate
the evolution of antibiotic resistance and serotype distribution
of S. pneumoniae in infections in children in Algeria.Material and methodsTABLE 1. Number of Streptococcus pneumoniae isolates by
sample origin and patient age
Sample
Patient age
Total<2 years 2–5 years >5–16 years
Invasive samples
CSF 30 10 13 53
Blood culture1 15 4 2 21
Puncture ﬂuids2 13 4 6 23
Total 58 18 21 97
Noninvasive samples
Lower respiratory tract samples 57 8 12 77
Auricular swabs 31 7 9 47
Sinus and nasal aspirates 5 10 29 44
Other samples3 0 3 2 5
Total 93 28 52 173
Overall total 151 46 73 270
1Pneumonia (n = 10), bacteremia (n = 11).
2Pleural (n = 15), joint (n = 5), peritoneal (n = 3).
3Conjunctive (n = 4), genital sample (n = 1).From January 2005 to June 2012, a total of 270 unique
S. pneumoniae isolates were collected from children aged 0 to
16 years with invasive and noninvasive infections; about 89%
were from Algiers and 11% from Oran, a town located in the
western part of the country. The hospital clinical laboratories
were asked to send all their viable isolates. Every year, the
centers isolate between 15 and 50 S. pneumoniae strains from
children who are diagnosed by physicians with invasive pneu-
mococcal disease (IPD) and non-IPD (NIPD). S. pneumoniae
isolates were identiﬁed by colony morphology, Gram staining,
catalase reaction, optochin susceptibility and bile lysis. Antibi-
otic susceptibilities for oxacillin, erythromycin, clindamycin,
tetracyclin, chloramphenicol and cotrimoxazole were deter-
mined following the Clinical and Laboratory Standards Institute
(CLSI) recommendations [11,12]. Minimum inhibitory concen-
trations (MICs) for penicillin, amoxicillin and cefotaxim were
determined using the E-test following the manufacturer’s in-
structions (Solna, Sweden) for all strains. The S. pneumoniae
ATCC 49619 strain was used for quality control.
Serotyping was performed by latex agglutination for deter-
mining pools, and serotypes were identiﬁed using the Neufeld
test (Pneumo test latex; Statens Serum Institute, Copenhagen,
Denmark). A total of 127 isolates were serotyped, 85 from
invasive samples and 42 from noninvasive samples. The isolates
that were serotyped were selected on the basis of the clinical
data, with priority given to IPD and the number of viable iso-
lates. Isolates were stored in 10% glycerol broth at −80°C after
primary isolation.New Microbes and New Infections © 2015 The Authors. Published by Elsevier Ltd on beha
This is an open access arResultsFrom the 270 isolates collected (IPD n = 97, NIPD n = 173),
197 (73.0%) were from children <5 years, of whom 151
(76.7%) were <2 years. Among the isolates from children with
IPD, 78.4% were collected from children <5 years of age, of
whom 76.3% were <2 years old. The IPD isolates were
collected from children with meningitis (n = 53), pneumonia
and pleuropneumonia (n = 25), bacteremia (n = 11), arthritis or
peritonitis infections (n = 8). The non-IPD isolates were from
ear, nose and throat infections (n = 91), bronchopulmonary
infections (n = 77) and other suppurative infections (n = 5).
Among the isolates from children with NIPD, 69.9% were from
children <5 years of age; 53.8% were <2 years old (Table 1).
Nonsusceptibility to penicillin was detected in 48% of the
S. pneumoniae isolates (MICs ranged from 0.016 μg/mL to 4 μg/
mL); 2.6% of isolates had intermediate resistance to amoxicillin;
7% and 1.7% of isolates had intermediate and full resistance to
cefotaxime, respectively. For the IPD isolates, the MIC90s were
2 μg/mL for penicillin and amoxicillin and 1.5 μg/mL for cefo-
taxime. The highest rate of cefotaxim resistance was observed
in isolates from meningitis: 20.8% intermediate and 3.8%
resistant (Table 2).
The percentages of isolates that were resistant to non-
β-lactam antibiotics were 53.0% for erythromycin and cotri-
moxazole; 43.7% for clindamycin; 42.0% for tetracycline; and
5.3% for chloramphenicol. According to the new breakpoints
suggested by CLSI, whereby meningitis and nonmeningitis iso-
lates have different breakpoints, 49.0% of the meningitis isolates
were resistant to penicillin (MIC 0.12 μg/mL), among which
26.9% had a MIC of 2 μg/mL.lf of European Society of Clinical Microbiology and Infectious Diseases, NMNI, 6, 42–48
ticle under the CC BY-NC-SA license (http://creativecommons.org/licenses/by-nc-sa/4.0/)
TABLE 2. MICs for penicillin, amoxicillin and cefotaxime in isolates from IPD and NIPD
Disease
Penicillin Amoxicillin Cefotaxime
I (%) R (%) MIC50 (μg/mL) MIC90 (μg/mL) I (%) R (%) MIC50 (μg/mL) MIC90 (μg/mL) I (%) R (%) MIC50 (μg/mL) MIC90 (μg/mL)
Meningitis (n = 53) 49 0.3 2 20.8 1.5 3.8 0.4
Other IPD (n = 44) 20.4 27.2 0.5 2 6.8 2.3 0.5 2 4.5 0 0.5 1.5
Total IPD (n = 97) 10 39.2 0.38 2 3.1 1 0.5 2 13.4 2 0.5 1.5
Otitis (n = 47) 25.5 10.6 0.8 2 0 0 1 2 0 0 0.5 1
LRTI (n = 77) 34.6 32.7 1 2 4.1 0 1.5 4 0 2 0.5 2
Other NIPD (n = 49) 34.2 2.5 0.2 1.5 2.5 0 0.3 2 2.5 0 0.2 1.5
Total NIPD (n = 173) 31.4 16 0.5 2 2.2 0 0.8 4 0.8 0.8 0.5 1.5
Global MICs were as follows: penicillin, I = 20.6%, R = 27.5%; amoxicillin, I = 2.56%, R = 0.42%; cefotaxime, I = 7%, R = 1.68%.
MIC, minimum inhibitory concentration; IPD, invasive pneumococcal disease; I, intermediate resistance; R, resistant; LRTI, lower respiratory tract infection; NIPD, noninvasive
pneumococcal disease.
44 New Microbes and New Infections, Volume 6 Number C, July 2015 NMNIAfter meningitis isolates, the next highest rate of penicillin-
nonsusceptible S. pneumoniae (PNSP) was observed in the
isolates from NIPD. From all the invasive isolates (n = 97),
40.3% were PNSP, with 81.5% of these from children <5 years
and 72.7% from children <2 years.
Among the 85 IPD samples that were serotyped, meningitis
was the most common diagnosis, at 50 (58.8%), followed by
pneumonia and pleuropneumonia, at 21 (24.7%), and bacter-
emia, at 9 (10.6%) (Table 3). The prevalence of IPD in children
aged <5 years and <2 years was 78.3% (n = 76) and 59.8%
(n = 58), respectively (Table 1). The most frequent serotypes
for invasive isolates were 14 (29.4%), 1 (10.6%), 19F (10.6%),
19A (7%), 6B (7%), 5 (4.7%), 3 (4.7%), 6A (3.5%) and 23F
(3.5%). Serotype 14 was the most prevalent in meningitis (34%)
and pleuropneumonia (28.6%), while serotypes 19F (38%) and
14 (23.8%) were the most frequent in noninvasive samples
(Table 3, Fig. I). In order of prevalence, serotypes 14, 19F, 6B,
19A, 1, 5, 23F, 6A, 3, 7F and 18C accounted for 91.0% of IPD in
children <5 years old. Serotypes 5, 7F, 6B, 18C and 19A were
found exclusively in children <2 years of age.
The serotypes that were most often antibiotic resistant were
14, 19F, 19A and 6B; they were mainly highly resistant to
penicillin, and only serotypes 14 and 19A were resistance to
cefotaxime (Fig. 2, Table 4).DiscussionThe prevalence of penicillin resistance among pneumococcal
disease isolates in Algeria, which was measured by the oxacillin
disc diffusion method, appears to have increased over the years,
from34.6% in 1995–2000 to 48.1% in 2005–2012 (current study)
[6–9]. The percentage of PNSP among IPD isolates in childrenwas
reported to be approximately 11% in Western European coun-
tries, with the highest percentage (49%) in Spain [1].
Our results are more consistent with the increasing antibi-
otic resistance rates reported for North African countries. For
instance, in Tunisia and Morocco, the rates of PNSP were,New Microbes and New Infections © 2015 The Authors. Published by Elsevier Ltd on behalf of
This is an open access article under the CC BY-NC-SA license (http://creativecommons.org/licerespectively, 52.8% and 43.3% [6–9,13–15]. The dramatic in-
crease in the antibiotic resistance rate since our previous study
(PNSP of 48.1% in this study compared with 34.6% in 2001)
could be explained by overuse of antibiotics for acute respi-
ratory tract infections in Algeria [8].
We also observed an evolution in the serotype distribution
in Algeria. Although the distribution is similar to that reported
for Morocco and Tunisia, as well as other developing countries,
it differs from that reported in our previous study, where we
found that serotypes/serogroups 1, 5, 14 and 6 were the most
frequent [8,9,15,16].
Some pneumococcal serotypes, such as serotypes 1, 5 and
7F, have more invasive potential than others; serotype 7F has
been reported to be associated with a higher risk of severe and
fatal outcomes [17]. In Africa, serotypes 1 and 5 are commonly
associated with invasive diseases. In Algeria, the frequency of
serotype 1 was low during the 2002–2004 and 2005–2007
periods but increased in 2008–2009 (unpublished data). Similar
observations of cyclical peaks in serotype 1 incidence have been
reported in many countries. Although serotypes 1 and 5 are
designated as ‘developing country serotypes,’ they have also
been reported to be frequently responsible for pediatric IPD in
industrialized countries such as Germany, Sweden and England
[18,19]. Serotype 1 has remained one of the most prevalent
invasive serotypes and is usually associated with meningitis
outbreaks in Africa and in crowded communities [16,20]. It is
ranked as one of the four serotypes with the highest IPD
burden in Africa, Asia and Latin American, while serotype 5 is
ranked third in Africa and Latin America and fourth in Asia [10].
In Thailand, the seven most frequent serotypes associated with
IPD in patients <5 years old were 6B, 23F, 14, 19F, 19A, 6A,
and 4 or 9V [21].
Two studies in Oxford and Stockholm that characterized the
genotypes and serotypes of nasopharyngeal and invasive pneu-
mococcal isolates from children and adults identiﬁed serotypes
1, 4 and 7F as having a high level of invasiveness, and serotypes
3 and 7F as having a higher case fatality rate compared with
other serotypes [22].European Society of Clinical Microbiology and Infectious Diseases, NMNI, 6, 42–48
nses/by-nc-sa/4.0/)
TABLE 3. Serotype distribution among isolates from children with IPD and NIPD
Serotype
Age <5 years Age 5–16 years
Overall
total
IPD (n [ 67) NIPD (n [ 35) IPD (n [ 18) NIPD (n [ 7)
Bacteremia Meningitis Pleuropneumonia
Other
IPD
Total IPD
for age
<5 years Otitis LRTI
Total
for age
<5 years Meningitis Pleuropneumonia
Bone and
joint infection Otitis LRTI
Total
for age
5–16 years
14 2 15 6 23 5 3 31 2 1 1 4 35
19F 2 3 2 7 10 6 23 2 2 25
6B 1 3 2 6 2 8 0 8
23F 1 0 1 2 2 4 1 1 5
18C 1 1 1 2 0 2
4 0 1 1 1
1 1 4 1 6 6 1 2 3 9
5 2 2 4 4 0 4
7F 1 1 2 2 0 2
3 2 2 1 3 2 1 3 6
6A 1 1 2 2 1 1 3
19A 2 2 2 6 4 10 0 10
35B 1 1 1 2 2 3
9A 1 1 1 1 1 2
16F 0 1 1 2 2
23B 1 1 1 1 2
6C 1 1 1 0 1
8 0 1 1 1
12 1 1 1 0 1
17F 0 1 1 1
23A 0 1 1 1
24A 0 1 1 1
28F 1 1 1 0 1
35F 1 1 1 0 1
Total 9 37 17 4 67 26 9 102 13 4 1 5 2 25 127
IPD, invasive pneumococcal disease; NIPD, noninvasive pneumococcal disease.
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FIG. 1. Serotype prevalence and pneu-
mococcal vaccine coverage of serotypes
isolated from children 5 years with inva-
sive pneumococcal disease. PCV, pneumo-
coccal conjugate vaccine.
46 New Microbes and New Infections, Volume 6 Number C, July 2015 NMNIThe predominant serotypes of PNSP in our study are similar
to those reported in other studies and previous studies in
Algeria, with the emergence of serotype 19A in the absence of
routine pneumococcal vaccination in our country [2,8,9,14,15].
The most commonly multidrug-resistant serotypes among the
PNSP were 19A, 19F, 14 and 6B, which were resistant to
erythromycin, cotrimoxazole, clindamycin and tetracycline.
Serotype 14 is one of the most invasive serotypes that can
cause life-threatening IPDs. Moreover, it can harbour multiple
resistance determinants, conferring resistance to penicillin,
erythromycin and cefotaxime [23]. In many countries the
multidrug-resistant serotype 19A has become the most pre-
dominant nonvaccine serotype isolated after PCV7 vaccination
[24].
On the basis of the serotype distribution observed in our
study, the PCV7 coverage in children <5 years of age with IPD
in Algeria is 55.3%, the PCV10 coverage is 71.1% and the
PCV13 coverage is 86.8%. This vaccine coverage among chil-
dren <2 years is 51.7% for PCV7, 69% for PCV10 and 87.9% for
PCV13. These data may not reﬂect the situation in all cases of
IPD in the studied regions because many children with IPD are0
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New Microbes and New Infections © 2015 The Authors. Published by Elsevier Ltd on behalf of
This is an open access article under the CC BY-NC-SA license (http://creativecommons.org/licetreated empirically. In addition, the limitations of existing
diagnostic tests affect the ability to obtain accurate IPD burden
data: only 10% of blood culture results are positive, so most
patients with pneumonia are not bacteriemic [25]. In Algeria,
the lack of laboratory facilities, including no facilities for storing
samples frozen at −80°C in different regions of the country, is
another limiting factor for conducting a multicenter study in
order to obtain accurate IPD burden data. Despite limited
ﬁnancial resources dedicated to IPD surveillance in Algeria, we
have conducted a nasopharyngeal carriage in healthy children
and the most prevalent serogroups were 6, 14 and 19 (23rd
European Congress of Clinical Microbiology and Infectious
Diseases, abstract R2717).
The pneumococcal conjugate vaccines (PCVs) currently
available have been shown to protect children. The ﬁrst
licensed 7-valent vaccine, which was widely used, resulted in
dramatic reductions in pneumococcal disease mortality and
morbidity. The emergence of the multidrug-resistant serotype
19A and the absence of the so-called developing country se-
rotypes, 1 and 5, has led manufacturers to develop higher
valency PCVs, such as PCV9, PCV10, PCV11 and PCV13 [26].28 F
Cefotaxime R
Cefotaxime I
Penicillin R
Penicillin I
FIG. 2. Resistance to penicillin and cefo-
taxime of Streptococcus pneumoniae sero-
types isolated from children 5 years. I,
intermediate resistance; R, resistant.
European Society of Clinical Microbiology and Infectious Diseases, NMNI, 6, 42–48
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TABLE 4. Resistance proﬁles by isolated S. pneumoniae serotypes
Antimicrobial 14 19F 6B 23F 5 7F 6A 19A 16F 24A 28F Total
oxa 2 2 4
oxa, sxt 10 1 11
oxa, sxt, tet 1 1
oxa, ery, clin 4 4
oxa, ery, clin, sxt 4 6 1 1 1 13
oxa, ery, clin, tet 1 7 2 1 11
oxa, ery, sxt, tet 1 1 1 3
oxa, ery, clin, sxt, tet 5 5 3 1 6 1 21
oxa, ery, clin, chl, sxt, tet 1 1
Total 28 20 5 2 1 1 1 8 1 1 1 69
oxa = oxacillin; sxt = cotrimoxazole; tet = tetracyclin; ery = erythromycin; clin = clindamycin; chl = chloramphenicol.
NMNI Ramdani-Bouguessa et al. Antimicrobial resistance in Algeria 47The WHO recommends the inclusion of PCVs in childhood
immunization programs worldwide, especially in countries with
childhood mortality that exceeds 50 deaths per 1000 births
[27]. Although there are some limitations with our study, the
results show that the burden of IPD is high in our country. The
good vaccine serotype coverage suggests that the introduction
of childhood vaccination with PCVs could be expected to have
a dramatic effect on the burden of IPD in our country.
Continuous national monitoring of IPD and nasopharyngeal
carriage as well as judicious use of antibiotics are crucial before
and after PCV implementation in order to evaluate the effect of
vaccination and to prevent the selection of multidrug-resistant
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